Rib-X amends IPO

Rib-X Pharmaceuticals Inc. (New Haven, Conn.) amended its IPO and now hopes to sell 10 million shares at $6-$7 per share. A $6.50 price would raise $65 million and value the company at $129.4 million. Deutsche Bank; William Blair; Lazard; and Needham are underwriters. Rib-X's delafloxacin, a broad spectrum fluoroquinolone antibiotic, is slated to begin Phase III testing next half to treat acute bacterial skin and skin structure infections (ABSSSI). ...